Univariate and multivariate analyses were conducted to identify the factors associated with ROP and the results are summarized in
Table 2. We found that increased rate of IVF was associated with the development of ROP (
P < 0.05), and maternal ICP was lower among infants with ROP than in infants without ROP (
P < 0.05). However, there were no differences in maternal age, primigravidity, cesarean delivery, singleton gestation, GDM, PE, PPROM, chorioamnionitis, placenta previa, placental abruption, and antenatal steroid use. We then analyzed neonatal factors contributing to ROP. The mean GA and BW in infants with ROP (29.7 ± 1.9 weeks, 1209.0 ± 186.1 g) were significantly lower than in those without ROP (30.9 ± 2.3 weeks, 1266.7 ± 182.7 g) (
P < 0.05). GA < 32 weeks, male sex, apnea, RDS, BPD, sepsis, PDA, and hyperglycemia were found to be statistically associated with ROP (
P < 0.05). Finally, we assessed the relationship between treatment modalities and ROP. We found that blood transfusion, invasive MV, and surfactant and dexamethasone use were significantly associated with ROP. However, the incidence rates of pneumonia, IVH, acidosis, hypoglycemia, and hyperbilirubinemia were not significantly different between the two groups. After multivariable adjustments, IVF (odds ratio [OR] = 1.896; 95% confidence interval [CI] 1.031–3.486), GA < 32 weeks (OR = 2.171; 95% CI 1.085–4.346), apnea (OR = 2.001; 95% CI 1.224–3.272), BPD (OR = 5.098; 95% CI 2.307–11.265), sepsis (OR = 2.212; 95% CI 1.070–4.576), PDA (OR = 1.675; 95% CI 1.011–2.774), and blood transfusion (OR = 1.819; 95% CI 1.046–3.163) were independently associated with the development of ROP (all
P < 0.05).